Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Kemp

Internal Medicine Shreveport, LA Medical Doctor

NPI 1972586527 CMS profile 44062

1460 E Bert Kouns Industrial Loop, Suite 700, Shreveport, LA 71105

Open in the dashboard

General payments

$3,130

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,299 paid to institutions, not to them · program year 2019

Through program year 2025, Susan Kemp of Shreveport, LA is reported in the CMS Open Payments database as having received $3,130 across 160 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,299 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $288 10
2024 General $282 13
2023 General $170 8
2022 General $503 10
2021 General $198 12
2020 General $348 13
2019 General $1,342 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Kemp
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Susan Kemp were reported at $288. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Susan Kemp Internal Medicine median Middle half National median
2019 $1,342 $159 $48–$570 $163
2020 $348 $119 $33–$402 $114
2021 $198 $135 $37–$521 $132
2022 $503 $141 $42–$496 $149
2023 $170 $149 $45–$519 $160
2024 $282 $154 $47–$537 $164
2025 $288 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $672 34 payments
  2. Organogenesis Inc. $405 11 payments
  3. AstraZeneca Pharmaceuticals LP $366 20 payments
  4. AbbVie, Inc. $194 12 payments
  5. Smith+Nephew, Inc. $181 8 payments
  6. Melinta Therapeutics, Inc. $158 9 payments
  7. Janssen Pharmaceuticals, Inc $134 11 payments
  8. UCB, Inc. $115 1 payment
  9. Paratek Pharmaceuticals, Inc. $110 5 payments
  10. Merck Sharp & Dohme Corporation $101 7 payments
  11. Other $696 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,126 159 payments
  2. Education $4 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $308 19 payments
  2. RYBELSUS $283 4 payments
  3. Puraply $199 4 payments
  4. COLLAGENASE SANTYL $151 6 payments
  5. FARXIGA $147 9 payments
  6. XARELTO $134 11 payments
  7. SYMBICORT $125 8 payments
  8. Apligraf $117 4 payments
  9. Tresiba $114 13 payments
  10. NUZYRA $110 5 payments
  11. Other $2,150 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 99 drugs

Part D claims

4,733

Median for Internal Medicine: 777

Drug cost

$486,985

Median for Internal Medicine: $73,373

Branded share of claims

20.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 85 $104,074
Ozempic Semaglutide Brand 73 $94,233
Januvia Sitagliptin Phosphate Brand 63 $64,845
Eliquis Apixaban Brand 47 $57,124
Jardiance Empagliflozin Brand 42 $37,382
Tresiba Flextouch U-200 Insulin Degludec Brand 31 $20,534
Trulicity Dulaglutide Brand 16 $20,055
Farxiga Dapagliflozin Propanediol Brand 12 $12,084
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 15 $11,143
Symbicort Budesonide/Formoterol Fumarate Brand 28 $7,560

The 10 drugs with the highest cost, of 99 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$69,103

Medicare's payments for the services billed

Medicare patients

258

Average age 74

Services billed

1,110

176 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 44%
Chronic kidney disease 28%
Ischemic heart disease 26%
Atrial fibrillation 19%
Depression 19%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $44
$44 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $42
$42 — —
Kimyrsa
  • Melinta Therapeutics, Inc. $21
$21 — —
RYBELSUS
  • Novo Nordisk Inc $10
$10 — —
Ozempic
  • Novo Nordisk Inc $10
$10 73 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record